Do analysts rate LIAN or ARTL?

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better earnings and valuation, LIAN or ARTL?

LianBio is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A

Is LIAN or ARTL more profitable?

LianBio's return on equity of -33.17% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Artelo Biosciences N/A -1,600.12% -224.62%

Do analysts recommend BFRG or ARTL?

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is BFRG or ARTL more profitable?

Bullfrog AI's return on equity of -217.80% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A -217.80% -174.57% Artelo Biosciences N/A -1,600.12% -224.62%

Do analysts recommend LNAI or ARTL?

Artelo Biosciences has a consensus target price of $54.00, suggesting a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable valuation & earnings, LNAI or ARTL?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A

Is LNAI or ARTL more profitable?

Lunai Bioworks' return on equity of -1,243.45% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Artelo Biosciences N/A -1,600.12% -224.62%

Do analysts rate FNCH or ARTL?

Artelo Biosciences has a consensus price target of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher valuation and earnings, FNCH or ARTL?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A

Is FNCH or ARTL more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Artelo Biosciences N/A -1,600.12% -224.62%

Which has preferable earnings and valuation, ARTL or CMMB?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A

Is ARTL or CMMB more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% Chemomab Therapeutics N/A -89.03% -79.68%

Artelo Biosciences (ARTL) Competitors

$1.16 -0.10 (-7.94%)

Closing price 04:00 PM Eastern

Extended Trading

$1.19 +0.03 (+2.24%)

As of 07:50 PM Eastern

Compare

ARTL vs. LIAN, BFRG, LNAI, FNCH, and CMMB

Should you buy Artelo Biosciences stock or one of its competitors? MarketBeat compares Artelo Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artelo Biosciences include LianBio (LIAN), Bullfrog AI (BFRG), Lunai Bioworks (LNAI), Finch Therapeutics Group (FNCH), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.

How does Artelo Biosciences compare to LianBio?

LianBio (NASDAQ:LIAN) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

LianBio's return on equity of -33.17% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Artelo Biosciences	N/A	-1,600.12%	-224.62%

LianBio is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market.

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

74.8% of LianBio shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, LianBio's average media sentiment score of 0.00 equaled Artelo Biosciences'average media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Artelo Biosciences	Neutral

Summary

LianBio beats Artelo Biosciences on 6 of the 10 factors compared between the two stocks.

How does Artelo Biosciences compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRG) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Bullfrog AI's return on equity of -217.80% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-217.80%	-174.57%
Artelo Biosciences	N/A	-1,600.12%	-224.62%

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Bullfrog AI had 1 more articles in the media than Artelo Biosciences. MarketBeat recorded 1 mentions for Bullfrog AI and 0 mentions for Artelo Biosciences. Bullfrog AI's average media sentiment score of 0.00 equaled Artelo Biosciences'average media sentiment score.

Company	Overall Sentiment
Bullfrog AI	Neutral
Artelo Biosciences	Neutral

Bullfrog AI has higher revenue and earnings than Artelo Biosciences. Bullfrog AI is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120K	99.50	-$6.50M	-$0.54	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bullfrog AI has a beta of -2.89, suggesting that its share price is 389% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market.

Summary

Bullfrog AI beats Artelo Biosciences on 8 of the 12 factors compared between the two stocks.

How does Artelo Biosciences compare to Lunai Bioworks?

Lunai Bioworks (NASDAQ:LNAI) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Lunai Bioworks' return on equity of -1,243.45% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Artelo Biosciences	N/A	-1,600.12%	-224.62%

Artelo Biosciences has a consensus target price of $54.00, suggesting a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Lunai Bioworks' average media sentiment score of 0.12 beat Artelo Biosciences' score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Neutral
Artelo Biosciences	Neutral

Lunai Bioworks is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lunai Bioworks has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market.

Summary

Artelo Biosciences beats Lunai Bioworks on 6 of the 11 factors compared between the two stocks.

How does Artelo Biosciences compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

In the previous week, Finch Therapeutics Group's average media sentiment score of 0.00 equaled Artelo Biosciences'average media sentiment score.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Artelo Biosciences	Neutral

Finch Therapeutics Group has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

Finch Therapeutics Group's return on equity of -69.14% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Artelo Biosciences	N/A	-1,600.12%	-224.62%

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Artelo Biosciences has a consensus price target of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Finch Therapeutics Group beats Artelo Biosciences on 6 of the 10 factors compared between the two stocks.

How does Artelo Biosciences compare to Chemomab Therapeutics?

Artelo Biosciences (NASDAQ:ARTL) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

Artelo Biosciences has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Artelo Biosciences presently has a consensus price target of $54.00, suggesting a potential upside of 4,555.17%. Chemomab Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 1,512.90%. Given Artelo Biosciences' higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics' return on equity of -89.03% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

In the previous week, Artelo Biosciences' average media sentiment score of 0.00 equaled Chemomab Therapeutics'average media sentiment score.

Company	Overall Sentiment
Artelo Biosciences	Neutral
Chemomab Therapeutics	Neutral

Summary

Chemomab Therapeutics beats Artelo Biosciences on 9 of the 11 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTL vs. The Competition

Export

Metric	Artelo Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.94M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.04	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	-0.61	8.26	10.76	6.41
Net Income	-$12.88M	$23.91M	$3.56B	$337.14M
7 Day Performance	-8.66%	3.05%	1.37%	-0.48%
1 Month Performance	-2.52%	2.40%	0.81%	0.49%
1 Year Performance	-93.36%	56.35%	30.53%	28.16%

Artelo Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTL Artelo Biosciences	1.2173 of 5 stars	$1.16 -7.9%	$54.00 +4,555.2%	-92.9%	$2.94M	N/A	N/A	5
LIAN LianBio	N/A	$0.11 -30.8%	N/A	-66.3%	$11.95M	N/A	N/A	110
BFRG Bullfrog AI	0.6416 of 5 stars	$0.69 +8.6%	N/A	-56.4%	$11.84M	$116.67K	N/A	4	News Coverage Gap Up
LNAI Lunai Bioworks	0.5068 of 5 stars	$2.85 +9.2%	N/A	N/A	$11.83M	N/A	N/A	20	High Trading Volume
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTL) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artelo Biosciences (ARTL) Competitors

ARTL vs. LIAN, BFRG, LNAI, FNCH, and CMMB

How does Artelo Biosciences compare to LianBio?

Summary

How does Artelo Biosciences compare to Bullfrog AI?

Summary

How does Artelo Biosciences compare to Lunai Bioworks?

Summary

How does Artelo Biosciences compare to Finch Therapeutics Group?

Summary

How does Artelo Biosciences compare to Chemomab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artelo Biosciences (ARTL) Competitors

ARTL vs. LIAN, BFRG, LNAI, FNCH, and CMMB

How does Artelo Biosciences compare to LianBio?

Is LIAN or ARTL more profitable?

Which has better earnings and valuation, LIAN or ARTL?

Which has more risk and volatility, LIAN or ARTL?

Do analysts rate LIAN or ARTL?

Do institutionals and insiders believe in LIAN or ARTL?

Does the media favor LIAN or ARTL?

Summary

How does Artelo Biosciences compare to Bullfrog AI?

Is BFRG or ARTL more profitable?

Do analysts recommend BFRG or ARTL?

Does the media refer more to BFRG or ARTL?

Which has stronger earnings & valuation, BFRG or ARTL?

Do insiders and institutionals believe in BFRG or ARTL?

Which has more volatility and risk, BFRG or ARTL?

Summary

How does Artelo Biosciences compare to Lunai Bioworks?

Is LNAI or ARTL more profitable?

Do analysts recommend LNAI or ARTL?

Does the media refer more to LNAI or ARTL?

Which has preferable valuation & earnings, LNAI or ARTL?

Do insiders & institutionals have more ownership in LNAI or ARTL?

Which has more volatility & risk, LNAI or ARTL?

Summary

How does Artelo Biosciences compare to Finch Therapeutics Group?

Does the media favor FNCH or ARTL?

Which has more risk & volatility, FNCH or ARTL?

Is FNCH or ARTL more profitable?

Which has higher valuation and earnings, FNCH or ARTL?

Do insiders and institutionals have more ownership in FNCH or ARTL?

Do analysts rate FNCH or ARTL?

Summary

How does Artelo Biosciences compare to Chemomab Therapeutics?

Do insiders and institutionals hold more shares of ARTL or CMMB?

Which has preferable earnings and valuation, ARTL or CMMB?

Which has more volatility and risk, ARTL or CMMB?

Do analysts prefer ARTL or CMMB?

Is ARTL or CMMB more profitable?

Does the media prefer ARTL or CMMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools